A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine (NCT07703475)
A Phase 1, Open-Label, Safety, Reactogenicity, and Immunogenicity Trial of RVX-sCPD9, a Live-Attenuated SARS-CoV-2, as a Booster Vaccine, Via the Intranasal Route in Previously Vaccinated Adults
🩺 Plain-English Summary (8th-Grade Level)
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of RVX-sCPD9, given Intranasally (IN), as a booster dose to previously vaccinated healthy adults. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating four dose levels of RVX-sCPD9 administered IN (10\^2, 10\^3, 10\^4, 5 x 10\^4 FFU). A sample size of 80 participants (20 participants in each cohort). The primary objective is to evaluate the safety and reactogenicity of a single IN administration of 4 ascending dosages of RVX-sCPD9 in previously vaccinated healthy adults.
Who can join: Review the eligibility criteria below.
Location: New York University School of Medicine - Langone Medical Center - Vaccine Center — New York, New York
Age range: 18 Years to 64 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- New York University School of Medicine - Langone Medical Center - Vaccine Center — New York, New York
- Duke Vaccine and Trials Unit — Durham, North Carolina
- Cincinnati Children's Hospital Medical Center Vaccine Research Center — Cincinnati, Ohio
- Baylor College of Medicine — Houston, Texas
📞 Contact the Study Coordinator
Phone: (877) 919-2822
Email: NYUVaccineCenter@nyulangone.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in COVID -19
- Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study — Bethesda, Maryland
- Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings — Trussville, Alabama
- A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19. — Las Vegas, Nevada
Explore by condition: All COVID -19 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.